DELIC Labs President and CSO Dr. Markus Roggen to Speak at MJBizCon

Dr. Roggen to Address the “Cost of the Status Quo: An Economic Look at Extraction Optimization”, Thursday Oct 21, 2021at 2:00pm PT

Vancouver, British Columbia – July 27, 2021 – DELIC Corp Inc. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced Dr. Markus Roggen, President and CEO of its subsidiary DELIC Labs has been selected as a speaker at MJBizCon 2021. Dr. Roggen will lead a discussion on “Cost of the Status Quo: An Economic Look at Extraction Optimization,” Thursday October 21, 2021 at 2:00pm PT. DELIC Labs is a federally-authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. DELIC Labs serves as the engine for the DELIC platform, conducting research and developing innovative product lines and intellectual property (IP), including psilocybin vaporization technology for future distribution across the Company’s physical footprint and licensed psychedelic wellness clinics in the United States.

“Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs,” said Dr. Roggen, DELIC Labs President and CSO. “The major obstacle to realize profits from an extraction operation is the disconnect between the business and production teams. Cannabis extraction should not be viewed as a black art but a quantifiable scientific process. And modern process analytics will improve the production and profits.”

Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis, DELIC Labs supports the psychedelic industry with high precision chemical analytics,  metabolomic identification and process optimization. DELIC Labs is one of a handful of licensed psilocybin research labs in Canada and has an aggressive plan to build out a suite of novel compounds and delivery methods for the industry. DELIC Labs is also a leading cannabis analytical and research company boasting clients that include some of the largest brands in the world. DELIC Labs is applying for a Dealer’s License, and intends to eventually commercialize its psilocybin research and associated intellectual property (IP).

Dr. Markus Roggen is President and Chief Scientific Officer of Delic Labs, a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Delic Labs is one of a handful of research labs licensed for both cannabis and psilocybin in Canada. Delic Labs was initially founded as Complex Biotech Discovery Ventures by Dr. Roggen and Prof. Dr. Glenn Sammis in 2018, and rebranded after the sale to Delic Corp. Dr. Roggen received his M/Sci degree from Imperial College, London, UK in 2008. He then pursued his graduate degree in organic chemistry at the Federal Institute of Technology in Zürich (ETHZ), where he received his PhD in 2012. Dr. Roggen was awarded an DAAD postdoctoral fellowship to pursue further training in physical organic chemistry at The Scripps Research Institute in La Jolla in 2013-2014. He then entered the cannabis industry in 2014 and since has held executive positions in analytical and production companies. His research into process optimization and analytical methods has been recognized with a number of awards, ElSohley Award of the ACS, Cannabis Scientist Power List 2020 & 2021, 40 under 40 by Marijuana Venture Magazine among others. Dr. Roggen is also a trusted advisor and mentor to multiple startups, startup accelerators and organizations

About DELIC Labs (formerly Complex Biotech Discovery Ventures Ltd.)

DELIC Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, DELIC Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the DELIC Corp family, the leading psychedelic wellness platform, DELIC Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.

About DELIC Corp, Inc.

DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. DELIC is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

Investor Relations Contact

Daniel Southan-Dwyer

Corporate Development

dsd@deliccorp.com

The Canadian Securities Exchange ‎has neither approved nor disapproved the contents of this news release and does not accept responsibility ‎for the adequacy or accuracy of this release.‎

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities ‎in the United States. The securities have not been and will not be registered ‎under the United States ‎Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state ‎securities laws and may not be offered or ‎sold within the United States unless registered under the U.S. ‎Securities Act and applicable state securities laws or an ‎exemption from such registration is available.‎

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of DELIC’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to, information concerning listing on the Canadian Securities Exchange, anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics), the continued emergence of psychedelics from stigmas, the ability of the Company to maintain sensible messaging, the ability of the Company to avoid dogmatic practices and binary rhetoric‎, the ability of DELIC to successfully achieve business ‎objectives, ‎and expectations ‎for other economic, ‎business, and/or competitive factors.‎

By identifying such information and statements in this manner, DELIC is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of DELIC to be ‎materially different from those ‎expressed or implied by such information and statements. In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, DELIC has made certain ‎assumptions. Among the key factors that could cause actual ‎results to differ materially from those projected in the ‎forward-looking information and statements are the ‎following: the ability to consummate the Proposed Transaction; ‎the ability to ‎obtain requisite regulatory and securityholder approvals and the satisfaction of ‎other conditions to the ‎consummation of the Proposed Transaction on the proposed terms and schedule; the ability to ‎satisfy the ‎conditions to the conversion of the Subscription ‎‎Receipts (as defined in the Previous Press Release); the potential impact of the announcement or consummation of the Proposed Transaction on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; compliance ‎with extensive government regulation; and the diversion ‎of management time on the Proposed Transaction.‎

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although DELIC believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and DELIC does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to DELIC or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN UNITED STATES